title: Intravitreal Ranibizumab for myopic choroidal neovascularization after pars plana vitrectomy and silicone oil tamponade.
abstract: OBJECTIVE
  To report on intravitreal Ranibizumab for intervening myopic choroidal neovascularization (CNV) in a case of retinal detachment successfully repaired with pars plana vitrectomy and silicone oil tamponade.
  
  
  METHODS
  Intravitreal ranibizumab was performed in a 67-year-old woman with CNV complicating pathologic myopia. The patient had previously undergone vitrectomy and silicone oil tamponade for retinal detachment.
  
  
  RESULTS
  At 2 months from intravitreal ranibizumab, best-corrected visual acuity (BCVA) improved from count fingers to 20/100, and intraocular pressure (IOP) was 16 mm Hg. Fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD-OCT) showed resolution of late leakage and subretinal/intraretinal fluid, respectively.
  
  
  CONCLUSIONS
  Administration of intravitreal anti-V EGF in patients with silicone oil as intraocular tamponade may represent an intriguing treatment option. Our results suggest that intravitreal injections of Ranibizumab may lead to a rapid improvement in both functional (BCVA) and morphologic (FA and SD-OCT) parameters of CNV activity, without significant rise in IOP, in eyes with silicone oil as intraocular tamponade.
authors.affiliation: 1 Department of Ophthalmology, Vita-Salute University, San Raffaele Scientific Institute, Milan - Italy.
authors.forename: Maria Lucia
authors.initials: ML
authors.lastname: Cascavilla
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Querques
authors.forename: Lea
authors.initials: L
authors.lastname: Querques
authors.forename: Marco
authors.initials: M
authors.lastname: Codenotti
authors.forename: Francesco
authors.initials: F
authors.lastname: Bandello
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D058450:Endotamponade; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007429:Intraocular Pressure; D058449:Intravitreal Injections; D047728:Myopia, Degenerative / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000601:surgery; D012827:Silicone Oils / Q000008:administration & dosage*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D012827:Silicone Oils; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab